Three safe and effective vaccines against SARS-CoV-2 have played a major role in combating COVID-19 in the United States. However, the effectiveness of these vaccines and vaccination programs has been challenged by the emergence of new SARS-CoV-2 variants of concern. A new mathematical model is formulated to assess the impact of waning and boosting of immunity against the Omicron variant in the United States. To account for gradual waning of vaccine-derived immunity, we considered three vaccination classes that represent high, moderate and low levels of immunity. We showed that the disease-free equilibrium of the model is globally-asymptotically, for two special cases, if the associated reproduction number is less than unity. Simulations of the model showed that vaccine-derived herd immunity can be achieved in the United States via a vaccination-boosting strategy which entails fully vaccinating at least $ 59\% $ of the susceptible populace followed by the boosting of about $ 72\% $ of the fully-vaccinated individuals whose vaccine-derived immunity has waned to moderate or low level. In the absence of boosting, waning of immunity only causes a marginal increase in the average number of new cases at the peak of the pandemic, while boosting at baseline could result in a dramatic reduction in the average number of new daily cases at the peak. Specifically, for the fast immunity waning scenario (where both vaccine-derived and natural immunity are assumed to wane within three months), boosting vaccine-derived immunity at baseline reduces the average number of daily cases at the peak by about 90% (in comparison to the corresponding scenario without boosting of the vaccine-derived immunity), whereas boosting of natural immunity (at baseline) only reduced the corresponding peak daily cases (in comparison to the corresponding scenario without boosting of natural immunity) by approximately 62%. Furthermore, boosting of vaccine-derived immunity is more beneficial (in reducing the burden of the pandemic) than boosting of natural immunity. Finally, boosting vaccine-derived immunity increased the prospects of altering the trajectory of COVID-19 from persistence to possible elimination.
Citation: Salman Safdar, Calistus N. Ngonghala, Abba B. Gumel. Mathematical assessment of the role of waning and boosting immunity against the BA.1 Omicron variant in the United States[J]. Mathematical Biosciences and Engineering, 2023, 20(1): 179-212. doi: 10.3934/mbe.2023009
Three safe and effective vaccines against SARS-CoV-2 have played a major role in combating COVID-19 in the United States. However, the effectiveness of these vaccines and vaccination programs has been challenged by the emergence of new SARS-CoV-2 variants of concern. A new mathematical model is formulated to assess the impact of waning and boosting of immunity against the Omicron variant in the United States. To account for gradual waning of vaccine-derived immunity, we considered three vaccination classes that represent high, moderate and low levels of immunity. We showed that the disease-free equilibrium of the model is globally-asymptotically, for two special cases, if the associated reproduction number is less than unity. Simulations of the model showed that vaccine-derived herd immunity can be achieved in the United States via a vaccination-boosting strategy which entails fully vaccinating at least $ 59\% $ of the susceptible populace followed by the boosting of about $ 72\% $ of the fully-vaccinated individuals whose vaccine-derived immunity has waned to moderate or low level. In the absence of boosting, waning of immunity only causes a marginal increase in the average number of new cases at the peak of the pandemic, while boosting at baseline could result in a dramatic reduction in the average number of new daily cases at the peak. Specifically, for the fast immunity waning scenario (where both vaccine-derived and natural immunity are assumed to wane within three months), boosting vaccine-derived immunity at baseline reduces the average number of daily cases at the peak by about 90% (in comparison to the corresponding scenario without boosting of the vaccine-derived immunity), whereas boosting of natural immunity (at baseline) only reduced the corresponding peak daily cases (in comparison to the corresponding scenario without boosting of natural immunity) by approximately 62%. Furthermore, boosting of vaccine-derived immunity is more beneficial (in reducing the burden of the pandemic) than boosting of natural immunity. Finally, boosting vaccine-derived immunity increased the prospects of altering the trajectory of COVID-19 from persistence to possible elimination.
| [1] |
S. T. Liang, L. T. Liang, J. M. Rosen, COVID-19: A comparison to the 1918 influenza and how we can defeat it, Postgrad Med. J., 97 (2021), 273–274. https://doi.org/10.1136/postgradmedj-2020-139070 doi: 10.1136/postgradmedj-2020-139070
|
| [2] | Worldometer, COVID-19 coronavirus pandemic, available from: https://www.worldometers.info/coronavirus/ (Accessed May 12, 2022). |
| [3] |
E. Dong, H. Du, L. Gardner, An interactive web-based dashboard to track COVID-19 in real time, Lancet Infect. Dis., 20 (2020), 533–534. https://doi.org/10.1016/S1473-3099(20)30120-1 doi: 10.1016/S1473-3099(20)30120-1
|
| [4] |
C. N. Ngonghala, E. Iboi, S. Eikenberry, M. Scotch, C. R. MacIntyre, M. H. Bonds, et al., Mathematical assessment of the impact of non-pharmaceutical interventions on curtailing the 2019 novel coronavirus, Math. Biosci., 325 (2020), 108364. https://doi.org/10.1016/j.mbs.2020.108364 doi: 10.1016/j.mbs.2020.108364
|
| [5] |
C. N. Ngonghala, E. A. Iboi, A. B. Gumel, Could masks curtail the post-lockdown resurgence of COVID-19 in the US?, Math. Biosci., 329 (2020), 108452. https://doi.org/10.1016/j.mbs.2020.108452 doi: 10.1016/j.mbs.2020.108452
|
| [6] |
C. N. Ngonghala, P. Goel, D. Kutor, S. Bhattacharyya, Human choice to self-isolate in the face of the Covid-19 pandemic: a game dynamic modelling approach, J. Theor. Biol., 521 (2021), 110692. https://doi.org/10.1016/j.jtbi.2021.110692 doi: 10.1016/j.jtbi.2021.110692
|
| [7] |
S. E. Eikenberry, M. Mancuso, E. Iboi, T. Phan, K. Eikenberry, Y. Kuang, et al., To mask or not to mask: Modeling the potential for face mask use by the general public to curtail the COVID-19 pandemic, Infect. Dis. Model., 5 (2020), 293–308. https://doi.org/10.1016/j.idm.2020.04.001 doi: 10.1016/j.idm.2020.04.001
|
| [8] |
C. N. Ngonghala, J. R. Knitter, L. Marinacci, M. H. Bonds, A. B. Gumel, Assessing the impact of widespread respirator use in curtailing COVID-19 transmission in the USA, Roy. Soc. Open Sci., 8 (2021), 210699. https://doi.org/10.1098/rsos.210699 doi: 10.1098/rsos.210699
|
| [9] | Pfizer, Pfizer and Biontech to submit emergency use authorization request today to the US FDA for COVID-19 vaccine, 2020. |
| [10] | US Food and Drug Administration, FDA briefing document, in: Oncology Drug Advisory Committee Meeting, Silver Spring, MD, 2009. |
| [11] | E. Mahase, COVID-19: Moderna vaccine is nearly 95% effective, trial involving high risk and elderly people shows, BMJ- Brit. Med. J., 371 (2020), m4471. |
| [12] |
W. H. Self, M. W. Tenforde, J. P. Rhoads, M. Gaglani, A. A. Ginde, D. J. Douin, et al., Comparative effectiveness of Moderna, Pfizer-Biontech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions—United States, March-August 2021, Morb. Mort. Wkly Rep., 70 (2021), 1337–1343. https://doi.org/10.15585/mmwr.mm7038e1 doi: 10.15585/mmwr.mm7038e1
|
| [13] | US Food and Drug Administration, FDA issues emergency use authorization for third COVID-19 vaccine, FSA News Release, 2021. |
| [14] | J. Sargent, S. Kumar, K. Buckley, J. McIntyre, Johnson & Johnson announces real-world evidence and phase 3 data confirming substantial protection of single-shot COVID-19 vaccine in the US additional data show a booster increases protection1, 2021. |
| [15] |
F. P. Polack, S. J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, et al., Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine, N. Engl. J. Med., 383 (2020), 2603–2615. https://doi.org/10.1056/NEJMoa2034577 doi: 10.1056/NEJMoa2034577
|
| [16] |
Y. M. Bar-On, Y. Goldberg, M. Mandel, O. Bodenheimer, L. Freedman, N. Kalkstein, et al., Protection of BNT162b2 vaccine booster against COVID-19 in Israel, N. Engl. J. Med., 385 (2021), 1393–1400. https://doi.org/10.1056/NEJMoa2114255 doi: 10.1056/NEJMoa2114255
|
| [17] |
E. Mahase, COVID-19: What new variants are emerging and how are they being investigated?, BMJ-Brit. Med. J., 372 (2021), n158. https://doi.org/10.1136/bmj.n158 doi: 10.1136/bmj.n158
|
| [18] |
A. Gómez-Carballa, J. Pardo-Seco, X. Bello, F. Martinón-Torres, A. Salas, Superspreading in the emergence of covid-19 variants, Trends Genet., 37 (2021), 1069–1080. https://doi.org/10.1016/j.tig.2021.09.003 doi: 10.1016/j.tig.2021.09.003
|
| [19] |
S. S. A. Karim, Q. A. Karim, Omicron Sars-Cov-2 variant: a new chapter in the COVID-19 pandemic, The Lancet, 398 (2021), 2126–2128. https://doi.org/10.1016/S0140-6736(21)02758-6 doi: 10.1016/S0140-6736(21)02758-6
|
| [20] |
D. Duong, What's important to know about the new COVID-19 variants?, CMAJ: Can. Med. Assoc. J., 193 (2021), E141–E142. https://doi.org/10.1503/cmaj.1095915 doi: 10.1503/cmaj.1095915
|
| [21] |
T. Koyama, D. Weeraratne, J. L. Snowdon, L. Parida, Emergence of drift variants that may affect COVID-19 vaccine development and antibody treatment, Pathogens, 9 (2020), 324. https://doi.org/10.3390/pathogens9050324 doi: 10.3390/pathogens9050324
|
| [22] |
C. Del Rio, S. B. Omer, P. N. Malani, Winter of omicron—the evolving COVID-19 pandemic, JAMA, 327 (2022), 319–320. https://doi.org/10.1001/jama.2021.24315 doi: 10.1001/jama.2021.24315
|
| [23] |
E. Callaway, H. Ledford, How bad is Omicron? what scientists know so far, Nature, 600 (2021), 197–199. https://doi.org/10.1038/d41586-021-03614-z doi: 10.1038/d41586-021-03614-z
|
| [24] | Center for Disease Control and Prevention, Omicron Variant: What You Need to Know, available from: https://www.cdc.gov/coronavirus/2019-ncov/variants/omicron-variant.html#., (Accessed May 09, 2022). |
| [25] |
F. Rahimi, A. T. B. Abadi, The Omicron subvariant BA. 2: Birth of a new challenge during the COVID-19 pandemic, Int. J. Surg., 99 (2022), 106261. https://doi.org/10.1016/j.ijsu.2022.106261 doi: 10.1016/j.ijsu.2022.106261
|
| [26] | K. Katella, Omicron and the BA.2 Subvariant: A Guide to What We Know, available from: https://www.yalemedicine.org/news/5-things-to-know-omicron, (Accessed May 09, 2022). |
| [27] | C. N. Ngonghala, H. B. Taboe, S. Safdar, A. B. Gumel, Unraveling the dynamics of the Omicron and Delta variants of the 2019 coronavirus in the presence of vaccination, mask usage, and antiviral treatment, medRxiv, (2022), 2022.02.23.22271394. https://doi.org/10.1101/2022.02.23.22271394 |
| [28] |
A. B. Gumel, E. A. Iboi, C. N. Ngonghala, G. A. Ngwa, Toward achieving a vaccine-derived herd immunity threshold for COVID-19 in the US, Front. Public Health, 9 (2021), 709369. https://doi.org/10.3389/fpubh.2021.709369 doi: 10.3389/fpubh.2021.709369
|
| [29] |
H. E. Fast, E. Zell, B. P. Murthy, N. Murthy, L. Meng, L. G. Scharf, et al., Booster and additional primary dose COVID-19 vaccinations among adults aged $\ge$ 65 years—United States, August 13, 2021–November 19, 2021, Morb. Mortal. Wkly Rep., 70 (2021), 1735. https://doi.org/10.15585/mmwr.mm7050e2 doi: 10.15585/mmwr.mm7050e2
|
| [30] |
E. A. Iboi, C. N. Ngonghala, A. B. Gumel, Will an imperfect vaccine curtail the COVID-19 pandemic in the US?, Infect. Dis. Model., 5 (2020), 510–524. https://doi.org/10.1016/j.idm.2020.07.006 doi: 10.1016/j.idm.2020.07.006
|
| [31] |
A. B. Gumel, E. A. Iboi, C. N. Ngonghala, E. H. Elbasha, A primer on using mathematics to understand Covid-19 dynamics: Modeling, analysis and simulations, Infect. Dis. Model., 6 (2020), 148–168. https://doi.org/10.1016/j.idm.2020.11.005 doi: 10.1016/j.idm.2020.11.005
|
| [32] | H. B. Taboe, M. Asare-Baah, A. Yesmin, C. N. Ngonghala, Impact of age structure and vaccine prioritization on COVID-19 in West Africa, Infect. Dis. Model., (2022). https://doi.org/10.1016/j.idm.2022.08.006 |
| [33] | C. N. Ngonghala, A. B. Gumel, Mathematical assessment of the role of vaccination against COVID-19 in the United States, in Mathematical Modeling, Simulations, and AI for Emergent Pandemic Diseases: Lessons Learned from COVID-19 (eds. Jorge X. Velasco Hernández and Esteban A. Hernandez-Vargas), Elsevier, (2022), 1–30. |
| [34] |
S. A. Rella, Y. A. Kulikova, E. T. Dermitzakis, F. A. Kondrashov, Rates of SARS-Cov-2 transmission and vaccination impact the fate of vaccine-resistant strains, Sci. Rep., 11 (2021), 1–10. https://doi.org/10.1038/s41598-021-95025-3 doi: 10.1038/s41598-021-95025-3
|
| [35] | B. Curley, How long does immunity from COVID-19 vaccination last?, Healthline, (Accessed on July 25, 2021). |
| [36] |
M. Mrityunjaya, V. Pavithra, R. Neelam, P. Janhavi, P. Halami, P. Ravindra, Immune-boosting, antioxidant and anti-inflammatory food supplements targeting pathogenesis of COVID-19, Front. Immunol., 11 (2020), 570122. https://doi.org/10.3389/fimmu.2020.570122 doi: 10.3389/fimmu.2020.570122
|
| [37] |
M. Alagawany, Y. A. Attia, M. R. Farag, S. S. Elnesr, S. A. Nagadi, M. E. Shafi, et al., The strategy of boosting the immune system under the COVID-19 pandemic, Front. Vet. Sci., (2021), 712. https://doi.org/10.3389/fvets.2020.570748 doi: 10.3389/fvets.2020.570748
|
| [38] | Food and Drug Administration, FDA briefing document, Pfizer-Biontech COVID-19 vaccine, in: Vaccines and Related Biological Products Advisory Committee Meeting, 2020. |
| [39] |
S. E. Oliver, J. W. Gargano, M. Marin, M. Wallace, K. G. Curran, et al., The Advisory Committee on Immunization Practices' interim recommendation for use of Pfizer-Biontech COVID-19 vaccine - United States, December 2020, Morb. Mortal. Wkly Rep., 69 (2020), 1922–1924. https://doi.org/10.15585/mmwr.mm6950e2 doi: 10.15585/mmwr.mm6950e2
|
| [40] | US Food and Drug Administration and others, Coronavirus (COVID-19) update: FDA issues policies to guide medical product developers addressing virus variants, FDA. February 23, 2021. |
| [41] |
L. Childs, D. W. Dick, Z. Feng, J. M. Heffernan, J. Li, G. Röst, Modeling waning and boosting of covid-19 in canada with vaccination, Epidemics, (2022), 100583. https://doi.org/10.1016/j.epidem.2022.100583 doi: 10.1016/j.epidem.2022.100583
|
| [42] | Centers for Disease Control and Prevention, CDC expands eligibility for COVID-19 booster shots to all adults, 2021. |
| [43] | W. Pacific, S. A. W. Hasan, Interim statement on booster doses for COVID-19 vaccination, Update, 4 (2021). |
| [44] | V. Lakshmikantham, A. Vatsala, Theory of differential and integral inequalities with initial time difference and applications, in: Analytic and Geometric Inequalities and Applications, Springer, Dordrecht. 1999, pp. 191–203. https://doi.org/10.1007/978-94-011-4577-0 |
| [45] |
H. W. Hethcote, The mathematics of infectious diseases, SIAM Rev., 42 (2000), 599–653. https://doi.org/10.1137/S0036144500371907 doi: 10.1137/S0036144500371907
|
| [46] |
P. Van den Driessche, J. Watmough, Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission, Math. Biosci., 180 (2002), 29–48. https://doi.org/10.1016/S0025-5564(02)00108-6 doi: 10.1016/S0025-5564(02)00108-6
|
| [47] |
O. Diekmann, J. A. P. Heesterbeek, J. A. Metz, On the definition and the computation of the basic reproduction ratio R0 in models for infectious diseases in heterogeneous populations, J. Math. Biol., 28 (1990), 365–382. https://doi.org/10.1007/BF00178324 doi: 10.1007/BF00178324
|
| [48] | V. Lakshmikantham, S. Leela, A. A. Martynyuk, Stability Analysis of Nonlinear Systems, Springer, 1989. |
| [49] |
A. B. Gumel, C. C. McCluskey, P. van den Driessche, Mathematical study of a staged-progression hiv model with imperfect vaccine, Bull. Math. Biol., 68 (2006), 2105–2128. https://doi.org/10.1007/s11538-006-9095-7 doi: 10.1007/s11538-006-9095-7
|
| [50] |
R. M. Anderson, The concept of herd immunity and the design of community-based immunization programmes, Vaccine, 10 (1992), 928–935. https://doi.org/10.1016/0264-410X(92)90327-G doi: 10.1016/0264-410X(92)90327-G
|
| [51] |
R. M. Anderson, R. M. May, Vaccination and herd immunity to infectious diseases, Nature, 318 (1985), 323–329. https://doi.org/10.1038/318323a0 doi: 10.1038/318323a0
|
| [52] | S. Pearson, What is the difference between the pfizer, moderna, and johnson & johnson covid-19 vaccines?, GoodRx (Accessed on June 25, 2021) (2021). |
| [53] |
M. Mancuso, S. E. Eikenberry, A. B. Gumel, Will vaccine-derived protective immunity curtail covid-19 variants in the US?, Infect. Dis. Model., 6 (2021), 1110–1134. https://doi.org/10.1016/j.idm.2021.08.008 doi: 10.1016/j.idm.2021.08.008
|
| [54] | Center for Disease Control and Prevention, It's Time for a Boost, available from: https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/past-reports/05202022.html, (Accessed July 08, 2022). |
| [55] |
D.-Y. Lin, Y. Gu, B. Wheeler, H. Young, S. Holloway, S.-K. Sunny, et al., Effectiveness of COVID-19 vaccines over a 9-month period in North Carolina, N. Engl. J. Med., 386 (2022), 933–941. https://doi.org/10.1056/NEJMoa2117128 doi: 10.1056/NEJMoa2117128
|
| [56] |
N. Andrews, J. Stowe, F. Kirsebom, S. Toffa, R. Sachdeva, C. Gower, et al., Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England, Nat. Med., 28 (2022), 831–837. https://doi.org/10.1038/s41591-022-01699-1 doi: 10.1038/s41591-022-01699-1
|
| [57] | S. M. Sidik, Vaccines protect against infection from Omicron subvariant-but not for long, Nature, 2022 Mar. https://doi.org/10.1038/d41586-022-00775-3 |
| [58] |
S. H. Tan, A. R. Cook, D. Heng, B. Ong, D. C. Lye, K. B. Tan, Effectiveness of BNT162b2 vaccine against Omicron in children 5 to 11 years of age, N. Engl. J. Med., 387 (2022), 525–532. https://doi.org/10.1056/NEJMoa2203209 doi: 10.1056/NEJMoa2203209
|
| [59] | R. Grewal, S. A. Kitchen, L. Nguyen, S. A. Buchan, S. E. Wilson, A. P. Costa, et al., Effectiveness of a fourth dose of COVID-19 mRNA vaccine against the Omicron variant among long term care residents in Ontario, Canada: test negative design study, BMJ, (2022), e071502. https://doi.org/10.1136/bmj-2022-071502 |
| [60] |
L. Jansen, B. Tegomoh, K. Lange, K. Showalter, J. Figliomeni, B. Abdalhamid, et al., Investigation of a SARS-Cov-2 B. 1.1. 529 (Omicron) variant cluster—Nebraska, November–December 2021, Morb. Mortal. Wkly Rep., 70 (2021), 1782–1784. https://doi.org/10.15585/mmwr.mm705152e3 doi: 10.15585/mmwr.mm705152e3
|
| [61] | B. Curley, "How long does immunity from COVID-19 vaccination last?"Healthline, available from: https://www.healthline.com/health-news/how-long-does-immunity-from-covid-19-vaccination-last, (Accessed March 22, 2022). |
| [62] |
N. M. Linton, T. Kobayashi, Y. Yang, K. Hayashi, A. R. Akhmetzhanov, S. Jung, et al., Incubation period and other epidemiological characteristics of 2019 novel coronavirus infections with right truncation: a statistical analysis of publicly available case data, J. Clin. Med., 9 (2020), 538. https://doi.org/10.3390/jcm9020538 doi: 10.3390/jcm9020538
|
| [63] | K. Weintraub, Enormous spread of Omicron may bring 140M new Covid infections to US in the next two months, model predicts, available from: https://www.wusa9.com/article/news/verify/how-long-does-it-take-for-the-vaccine-booster-to-get-to-full-protection/65-aa7344c2-fcd5-4c70-bbcd-046e9f697be7, (Accessed March 22, 2022). |
| [64] | M. Gregory, M. Salenetri, How long does immunity from COVID-19 vaccination, available from: https://www.wusa9.com/article/news/verify/how-long-does-it-take-for-the-vaccine-booster-to-get-to-full-protection/65-aa7344c2-fcd5-4c70-bbcd-046e9f697be7, (Accessed March 22, 2022). |
| [65] |
M. G. Thompson, Effectiveness of a third dose of mRNA vaccines against COVID-19–associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance—VISION Network, 10 States, August 2021–January 2022, Morb. Mortal. Wkly Rep., 71 (2022), 139–145. https://doi.org/10.15585/mmwr.mm7104e3 doi: 10.15585/mmwr.mm7104e3
|
| [66] | J. Bosman, J. Hoffman, M. Sanger-Katz, T. Arango, Who are the unvaccinated in America? there's no one answer, The New York Times, 2021. |
| [67] |
J. K. Tan, D. Leong, H. Munusamy, N. H. Zenol Ariffin, N. Kori, R. Hod, et al., The prevalence and clinical significance of Presymptomatic COVID-19 patients: how we can be one step ahead in mitigating a deadly pandemic, BMC Infect. Dis., 21 (2021), 1–10. https://doi.org/10.1186/s12879-021-05849-7 doi: 10.1186/s12879-021-05849-7
|
| [68] | S. Desmon, COVID and the Heart: It Spares No One, available from: https://publichealth.jhu.edu/2022/covid-and-the-heart-it-spares-no-one, (Accessed August 30, 2022). |
| [69] |
V. Thakur, R. K. Ratho, Omicron (b. 1.1. 529): A new SARS-CoV-2 variant of concern mounting worldwide fear, J. Med. Virol., 94 (2022), 1821–1824. https://doi.org/10.1002/jmv.27541 doi: 10.1002/jmv.27541
|
| [70] |
J. M. Dan, J. Mateus, Y. Kato, K. M. Hastie, E. D. Yu, C. E. Faliti, et al., Immunological memory to SARS-Cov-2 assessed for up to 8 months after infection, Science, 371 (2021), eabf4063. https://doi.org/10.1126/science.abf4063 doi: 10.1126/science.abf4063
|
| [71] |
J. M. Ferdinands, S. Rao, B. E. Dixon, P. K. Mitchell, M. B. DeSilva, S. A. Irving, et al., Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19–associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance—vision network, 10 states, August 2021–January 2022, Morb. Mortal. Wkly Rep., 71 (2022), 255–263. https://doi.org/10.15585/mmwr.mm7107e2 doi: 10.15585/mmwr.mm7107e2
|
| [72] | Z. Zhongming, L. Linong, Y. Xiaona, Z. Wangqiang, L. Wei, Omicron largely evades immunity from past infection or two vaccine doses, 2021. |
| [73] |
P. Elliott, O. Eales, B. Bodinier, D. Tang, H. Wang, J. Jonnerby, et al., Dynamics of a national Omicron SARS-CoV-2 epidemic during {J}anuary 2022 in England, Nat. Commun., 13 (2022), 1–10. https://doi.org/10.1038/s41467-022-32121-6 doi: 10.1038/s41467-022-32121-6
|
| [74] | P. Elliott, O. Eales, N. Steyn, D. Tang, B. Bodinier, H. Wang, et al., Twin peaks: the Omicron SARS-CoV-2 BA. 1 and BA. 2 epidemics in England, Science, (2022), eabq4411. https://doi.org/10.1126/science.abq4411 |
| [75] |
D. Kim, S. T. Ali, S. Kim, J. Jo, J.-S. Lim, S. Lee, et al., Estimation of serial interval and reproduction number to quantify the transmissibility of SARS-CoV-2 Omicron variant in South Korea, Viruses, 14 (2022), 533. https://doi.org/10.3390/v14030533 doi: 10.3390/v14030533
|
| [76] |
H. F. Tseng, B. K. Ackerson, Y. Luo, L. S. Sy, C. A. Talarico, Y. Tian, et al., Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants, Nat. Med., 28 (2022), 1063–1071. https://doi.org/10.1038/s41591-022-01753-y doi: 10.1038/s41591-022-01753-y
|
| [77] |
H. Chemaitelly, H. H. Ayoub, S. AlMukdad, P. Coyle, P. Tang, H. M. Yassine, et al., Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA. 1 and BA. 2 subvariants in Qatar, Nat. Commun., 13 (2022), 3082. https://doi.org/10.1038/s41467-022-30895-3 doi: 10.1038/s41467-022-30895-3
|
Figures(7) / Tables(5)
Salman Safdar, Calistus N. Ngonghala, Abba B. Gumel. Mathematical assessment of the role of waning and boosting immunity against the BA.1 Omicron variant in the United States[J]. Mathematical Biosciences and Engineering, 2023, 20(1): 179-212. doi: 10.3934/mbe.2023009
DownLoad: